Literature DB >> 27863659

Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity.

Sara Pereira1, Raphael Egbu1, Gemma Jannati1, Wafa' T Al-Jamal2.   

Abstract

Docetaxel (DTX)-loaded liposomes have been formulated to overcome DTX solubility issue, improve its efficacy and reduce its toxicity. This study investigated the effect of steric stabilisation, varying liposome composition, and lipid:drug molar ratio on drug loading and on the physicochemical properties of the DTX-loaded liposomes. Size exclusion chromatography (SEC) was used to remove free DTX from the liposomal formulation, and its impact on drug loading and in vitro cytotoxicity was also evaluated. Liposomes composed of fluid, unsaturated lipid (DOPC:Chol:DSPE-PEG2000) showed the highest DTX loading compared to rigid, saturated lipids (DPPC:Chol:DSPE-PEG2000 and DSPC:Chol:DSPE-PEG2000). The inclusion of PEG showed a minimum effect on DTX encapsulation. Decreasing lipid:drug molar ratio from 40:1 to 5:1 led to an improvement in the loading capacities of DOPC-based liposomes only. Up to 3.6-fold decrease in drug loading was observed after liposome purification, likely due to the loss of adsorbed and loosely entrapped DTX in the SEC column. Our in vitro toxicity results in PC3 monolayer showed that non-purified, DTX-loaded DOPC:Chol liposomes were initially (24h) more potent than the purified ones, due to the fast action of the surface- adsorbed drug. However, we hypothesize that over time (48 and 72h) the purified, DTX-loaded DOPC:Chol liposomes became more toxic due to high intracellular release of encapsulated DTX. Finally, our cytotoxicity results in PC3 spheroids showed the superior activity of DTX-loaded liposomes compared to free DTX, which could overcome the DTX poor tissue penetration, drug resistance, and improve its therapeutic efficacy following systemic administration. Crown
Copyright © 2016. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Docetaxel; Liposome; PC3; Prostate cancer; Purification; Spheroid

Mesh:

Substances:

Year:  2016        PMID: 27863659     DOI: 10.1016/j.ijpharm.2016.06.057

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  11 in total

1.  Transfersome Hydrogel Containing 5-Fluorouracil and Etodolac Combination for Synergistic Oral Cancer Treatment.

Authors:  Srivarsha Reddy Bollareddy; Vandana Krishna; Girdhari Roy; Deepika Dasari; Arti Dhar; Venkata Vamsi Krishna Venuganti
Journal:  AAPS PharmSciTech       Date:  2022-02-07       Impact factor: 3.246

2.  Enhancing Docetaxel Delivery to Multidrug-Resistant Cancer Cells with Albumin-Coated Nanocrystals.

Authors:  Sheryhan F Gad; Joonyoung Park; Ji Eun Park; Gihan N Fetih; Sozan S Tous; Wooin Lee; Yoon Yeo
Journal:  Mol Pharm       Date:  2018-01-29       Impact factor: 4.939

3.  Wheat Germ Agglutinin-Conjugated Disulfide Cross-Linked Alginate Nanoparticles as a Docetaxel Carrier for Colon Cancer Therapy.

Authors:  Hock Ing Chiu; Vuanghao Lim
Journal:  Int J Nanomedicine       Date:  2021-04-22

4.  Co-encapsulation of thymoquinone with docetaxel enhances the encapsulation efficiency into PEGylated liposomes and the chemosensitivity of MCF7 breast cancer cells to docetaxel.

Authors:  Fadwa Odeh; Randa Naffa; Hanan Azzam; Ismail S Mahmoud; Walhan Alshaer; Abeer Al Bawab; Said Ismail
Journal:  Heliyon       Date:  2019-11-27

5.  A novel adjuvant drug-device combination tissue scaffold for radical prostatectomy.

Authors:  Ketevan Paliashvili; Francesco Di Maggio; Hei Ming Kenneth Ho; Sanjayan Sathasivam; Hashim Ahmed; Richard M Day
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

6.  Magneto-Liposomes as MRI Contrast Agents: A Systematic Study of Different Liposomal Formulations.

Authors:  Nina Kostevšek; Calvin C L Cheung; Igor Serša; Mateja Erdani Kreft; Ilaria Monaco; Mauro Comes Franchini; Janja Vidmar; Wafa T Al-Jamal
Journal:  Nanomaterials (Basel)       Date:  2020-05-06       Impact factor: 5.076

7.  Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles.

Authors:  Wei Zhang; Yunmei Song; Preethi Eldi; Xiuli Guo; John D Hayball; Sanjay Garg; Hugo Albrecht
Journal:  Int J Nanomedicine       Date:  2018-01-09

8.  Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.

Authors:  Anne Rodallec; Jean-Michel Brunel; Sarah Giacometti; Helene Maccario; Florian Correard; Eric Mas; Caroline Orneto; Ariel Savina; Fanny Bouquet; Bruno Lacarelle; Joseph Ciccolini; Raphaelle Fanciullino
Journal:  Int J Nanomedicine       Date:  2018-06-18

9.  Optimization of Docetaxel Loading Conditions in Liposomes: proposing potential products for metastatic breast carcinoma chemotherapy.

Authors:  Roghayyeh Vakili-Ghartavol; Seyed Mahdi Rezayat; Reza Faridi-Majidi; Kayvan Sadri; Mahmoud Reza Jaafari
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

10.  A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model.

Authors:  Isabella Orienti; Ferro Nguyen; Peng Guan; Venkatadri Kolla; Natalia Calonghi; Giovanna Farruggia; Michael Chorny; Garrett M Brodeur
Journal:  Drug Des Devel Ther       Date:  2019-12-19       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.